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The Gram negative bacterium Yersinia pestis can infect humans by multiple routes to cause 
plague. Three plague pandemics have occurred and Y. pestis has been linked to biowarfare in 
the past. The continued risk of plague as a bioweapon has prompted increased research to 
understand Y. pestis pathogenesis and develop new plague therapeutics. Several in vivo models 
have been developed for this research and are reviewed here. 
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monic. Bubonic plague, the most common form, arises after trans-
mission of Y. pestis from an infected flea. The incubation period for 
bubonic plague is 2–8 days after exposure. During this incubation 
period, Y. pestis disseminates from the bite site to the regional lymph 
node. There the bacteria evade immune clearance and proliferate 
to high numbers. Patients initially present with flu-like symptoms, 
highlighted by the sudden onset of fever, chills, lethargy, and head-
ache (Butler, 1983; Dennis, 2005; Adamovicz and Worsham, 2006). 
As the bacteria continue to proliferate, patients develop extremely 
painful swollen lymph nodes called buboes. Eventually these tissues 
will contain enormous numbers of extracellular bacteria. Typically 
patients present with a single bubo at the draining lymph node of 
the bite site. Infected lymph nodes become severely damaged, and 
pathology is characterized by hemorrhage and necrosis (Flexner, 
1901). Without treatment, bubonic plague mortality rates approach 
60%. However, bubonic plague responds well to antibiotic treat-
ment, and mortality rates with proper treatment have dropped to 
below 5% (Dennis, 2005).
Bubonic plague can progress to septicemic plague if bacteria 
enter the blood stream. Septicemic plague is characterized by high 
bacteremia and is accompanied by a dangerous endotoxemia. In 
rare cases, Y. pestis can directly infect the blood and cause septicemic 
plague without presenting with symptoms of bubonic plague (called 
primary septicemic plague). Septicemic patients often have fever, 
severe headache, and lethargy but may also present with gatrointes-
tinal symptoms (nausea, vomiting, diarrhea, and abdominal pain). 
Without the clinical development of buboes, septicemic patients 
are often not diagnosed with plague until Y. pestis is identified in 
blood smears. By this time the prognosis for infected patients is 
poor, and mortality rates are high even with antibiotic treatment 
(Butler, 1983).
In a small percentage of bubonic patients, Y. pestis can spread 
hematogenously to other tissues, including the lungs. Lung coloniza-
tion can lead to the development of secondary pneumonic plague 
IntroductIon
Plague is caused by the Gram negative pathogen Y. pestis. The bacte-
rium exists in nature in a zoonotic cycle between mammalian hosts and 
the flea transmission vector (Perry and Fetherston, 1997; Ligon, 2006). 
Contact with infected fleas or animals can result in the transmission 
of Y. pestis to humans. In humans, plague infection can manifest in 
one of three forms based on transmission route and tissues infected. 
Bubonic plague is a result of flea transmission and is characterized 
by the development of swollen, infected lymph nodes called buboes. 
The bacteria will eventually enter the blood stream to cause septicemic 
plague and disseminate to other tissues. Colonization of the lungs 
results in secondary pneumonic plague and the possibility of person 
to person transmission through aerosol droplets (primary pneumonic 
plague). Plague infection rapidly progresses and is associated with a 
high mortality rate in untreated individuals (70–100%). Successful 
treatment of infection is greatly increased with early detection. 
Three plague pandemics have occurred, resulting in the death of 
over a third of the population of Europe and impacting the devel-
opment of Western societies (Perry and Fetherston, 1997; Ligon, 
2006). While plague has been considered a historic disease, con-
cerns about the use of Y. pestis as a biological weapon and isolation 
of antibiotic resistant Y. pestis strains from nature have increased 
efforts to understand plague pathogenesis and develop novel thera-
peutics (Galimand et al., 1997; Inglesby et al., 2000). Researchers are 
equipped with a variety of tools to dissect the virulence mechanisms 
of Y. pestis and develop new approaches to combat the potential use 
of plague as a bioweapon. Here, we will discuss models of plague 
infection, their potential for use in defining plague pathogenesis, 
and their importance in translational research.
Human Plague
Humans are considered accidental hosts for Yersinia pestis and are 
extremely susceptible to infection. Human plague can present in 
infected patients in three forms: bubonic, septicemic, and pneu-Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 119  |  2
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models to study Yersinia pestis PatHogenesIs and 
develoP new Plague tHeraPeutIcs
With the growing concern about antibiotic resistant strains of Y. 
pestis (Galimand et al., 1997) and the potential risk of a plague 
bioweapon (Inglesby et al., 2000), development of plague vac-
cine candidates and new post-exposure treatments are becoming 
increasingly important. These objectives have driven research to 
better understand the interactions between Y. pestis and its hosts. 
Systems to model insect and human infection are essential for these 
studies. Animal models of plague have been used by researchers 
for over 100 years. These important studies have included multiple 
different species and have established the progression of plague 
pathology and the potential of vaccine candidates (Adamovicz and 
Worsham, 2006). More recently, researchers have further character-
ized specific models to provide powerful tools to dissect aspects of 
Y. pestis pathogenesis, including interactions between the bacterium 
and host cells, transmission from the insect vector, infection of the 
mammalian host, and host immune responses during infection. 
This review will highlight recent developments in several common 
models used for plague research to understand Y. pestis pathogenesis 
and develop new therapeutic and vaccine candidates.
Invertebrate models to study transmIssIon factors
Y. pestis is the only enteric bacterium to use an insect vector as its 
primary mode of transmission. The acquisition of genetic elements 
referred to as transmission factors allows for successful transmis-
sion from insect to mammal and back to insect. Transmission fac-
tors appear to be distinct from virulence genes that are required 
to cause mammalian disease (Hinnebusch et al., 1996; Paskewitz, 
1997). Y. pestis primarily uses fleas for transmission and infects at 
least 80 different species (Pollitzer, 1954; Hinnebusch, 2005). In 
1914, Bacot and Martin first described the mechanism for Y. pestis 
flea transmission using the rat flea Xenopsylla cheopis, which is a 
very efficient species for transmission (Bacot and Martin, 1914; 
Hirst, 1923). Their studies were highlighted by the observation that 
Y. pestis forms bacterial aggregates that block the feeding appara-
tus (proventriculus) of the flea. This blockage inhibits successful 
feeding by the flea and results in regurgitation of Y. pestis-infected 
blood back into the bite site and transmission of the bacterium 
into the mammalian host.
As the flea is the natural transmission vector for Y. pestis, it is a 
logical system to study Y. pestis-insect interactions. Furthermore, 
because X. cheopis is highly efficient in transmitting Y. pestis to the 
mammalian host in the laboratory setting, it has been used as a 
model to identify Y. pestis transmission factors (Hinnebusch, 2005). 
For example, the Yersinia murine toxin (Ymt) was first described 
due to its toxicity to mice (Warren et al., 1955). However, the ymt 
gene was subsequently shown to be dispensable during mouse 
infection,  and  ymt  mutants  are  fully  virulent  (Drozdov  et  al., 
1995; Hinnebusch et al., 1996). While Ymt is not a virulence fac-
tor in mammals, it appears to be an important transmission factor. 
Studies by Hinnebusch et al. with the flea model demonstrated that 
Ymt is required for colonization of the flea midgut. ymt(−) mutants 
are rapidly cleared from the midgut before the bacteria block the 
proventriculus (Hinnebusch et al., 2002). Interestingly, transfer of 
ymt into Y. pseudotuberculosis significantly increased the ability of 
this enteric pathogen to survive in the flea midgut. These findings 
and the possibility of person to person transmission. Inhalation 
of aerosols containing Y. pestis can result in primary pneumonic 
plague in naive individuals. Primary pneumonic plague has a short 
incubation period of 1–2 days, followed by sudden onset of symp-
toms (fever, headache, chest pain, cough) and rapid progression of 
infection. Patients can present with localized bronchopneumonia or 
segmental to confluent consolidation of the lungs. Primary pneu-
monic infection is an extremely acute disease. Death can occur in as 
little as 3 days post-exposure. Furthermore, for antibiotic treatment 
to be effective, therapy needs to administered within 20 h of onset 
of illness (McCrumb et al., 1953; Butler, 1983). While pneumonic 
infection is a rare occurrence under natural situations, because of its 
ability for aerosol transmission and the acute nature of the infection, 
Y. pestis is also a potential bioweapon (Inglesby et al., 2000; Dennis, 
2005). Prophylactic antibiotic treatment after a possible exposure 
can protect individuals from developing pneumonic plague, but 
new therapeutics and vaccines are needed to ensure protection in 
the event of a biological attack with weaponized Y. pestis.
Currently, no FDA licensed plague vaccines are available in the 
United States. However, both killed and live-attenuated vaccine 
candidates have been used in the past. Haffkine first described the 
use of a killed vaccine in 1879. Individuals were vaccinated with a 
heat-killed culture of fully virulent Y. pestis. Side effects associated 
with the vaccine included high incidence of localized pain, lym-
phadenopathy, fever, headache, and weakness. A small number of 
immunized individuals still contracted plague, suggesting that the 
vaccine was not fully protective (Meyer et al., 1974a). A formalin-
killed vaccine called Plague Vaccine, USP was developed in the 
1930s and administered to military personnel. Vaccination with 
Plague Vaccine, USP elicited antibody responses in humans and 
is believed to have protected personnel against plague infection 
during the Vietnam War (Meyer, 1970). However, adverse reac-
tions similar to the heat-killed vaccine were also reported in Plague 
Vaccine, USP vaccinated individuals. Furthermore, evidence from 
vaccinated rodents, non-human primates (NHPs), and humans 
suggests that the formalin-killed vaccine did not provide complete 
protection against pneumonic infection (Smiley, 2008a). The Y. 
pestis E.V. strain (and its derivative EV76) is a pigment-negative 
attenuated strain that has been used as a live vaccine in millions 
of people. Vaccination with this strain appears to provide protec-
tion against both bubonic and pneumonic plague. However, as a 
live bacterial vaccine, safety concerns are associated with vaccina-
tion and stem from a high frequency of debilitating side effects in 
humans and reports of primates dying as a result of vaccination 
(Meyer et al., 1974a; Smiley, 2008a).
More recently a subunit vaccine containing the F1 and LcrV 
antigens of Y. pestis has entered into clinical trials. Phase 1 trials to 
examine safety and immunogenicity of the F1 and LcrV subunits 
demonstrated that vaccination resulted primarily in a TH2 response 
of varying degrees (Williamson et al., 2005). Sera from vaccinated 
individuals passively protected mice from Y. pestis infection, indi-
cating that protective immunity was achieved. However, antibody 
titers did not correlate with degree of protection. Studies to further 
examine the efficacy of this vaccine and others is difficult due to 
the low number of human plague cases. Future studies will likely 
rely on the results of animal vaccination studies and development 
of protective correlates that can be tested in humans.www.frontiersin.org  November 2010  | Volume 1  | Article 119  |  3
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tHe macroPHage model to study Plague InteractIons  
wItH Host cells
Cavanaugh and Randall first suggested that Y. pestis entering the 
mammalian host from infected fleas are not resistant to phagocyto-
sis and can be phagocytized by either monocytes or polymorphonu-
clear cells (PMNs). In these studies, bacteria that are phagocytized by 
PMNs were readily killed, but bacteria phagocytized by monocytes 
survived, replicated, and emerged resistant to further phagocytosis 
by both cell types (Cavanaugh and Randall, 1959). These observa-
tions have been confirmed by electron microscopy of monocytes 
from plague infected Rhesus macaques and by flow cytometry of 
infected cells in the spleens of plague infected mice (Finegold, 1969; 
Lukaszewski et al., 2005). Furthermore, depletion of macrophages 
prior to Y. pestis infection resulted in a better outcome for the host 
(Ye et al., 2009). These findings have contributed to the hypothesis 
that Y. pestis is a facultative intracellular pathogen that invades mac-
rophages early in the infection process to avoid clearance by PMNs, 
and later emerges from macrophages expressing virulence factors 
(Caf1, T3SS effectors, etc.) to inhibit subsequent phagocytosis. Y. 
pestis invasion of macrophages may also contribute to the delay in 
the host immune response seen during plague infection.
In vitro studies with macrophages have confirmed in vivo find-
ings that Y. pestis is a facultative intracellular pathogen (Janssen 
and  Surgalla,  1969;  Straley  and  Harmon,  1984a,b;  Charnetzky 
and Shuford, 1985; Pujol and Bliska, 2003). Upon phagocytosis, 
Y. pestis enters into a phagocytic vacuole called the Yersinia con-
taining vacuole (YCV). YCVs acquire markers of late endosomes 
and lysosomes, but Y. pestis appears to inhibit their normal acidi-
fication, suggesting that it resides within macrophages in modi-
fied phagolysosomal compartments (Straley and Harmon, 1984b; 
Grabenstein et al., 2006; Pujol et al., 2009). The bacteria remain 
in these spacious vacuoles and eventually begin to replicate. The 
mechanisms used by Y. pestis, and the host factors targeted by the 
bacterium to alter the normal phagocytic pathway, are not well 
understood. However, Straley and Harmon have demonstrated that 
virulence factors known to be important for mammalian infection, 
including factors on the pCD1 virulence plasmid, are not required 
for survival in macrophages (Straley and Harmon, 1984a). These 
findings suggest that additional factors are important for macro-
phage infection.
Several studies have demonstrated that the in vitro macro-
phage model can be used to identify intracellular pathogenicity 
factors. Oyston et al. (2000) demonstrated that survival of Y. pestis 
in J774A.1 macrophage-like cells is dependent on the two com-
ponent regulator PhoP/Q. Graberstein et al. (2006) further dem-
onstrated that phoP mutants failed to develop spacious vacuoles 
in infected J774A.1 cells and that three genes regulated by PhoP 
(ugd, pmrK, and mgtC) contribute to Y. pestis survival in these cells. 
Furthermore, Y. pestis phoP mutants were also attenuated in mouse 
infection, supporting the hypothesis that macrophage survival may 
be important for Y. pestis virulence (Oyston et al., 2000). Unlike 
phoP/Q, the rip operon appears to specifically contribute to survival 
of Y. pestis in activated macrophages (Pujol et al., 2005). However, 
the contribution of the rip operon to mammalian virulence has 
not yet been determined. Together, these findings demonstrate that 
the macrophage model can be used to identify pathogenesis factors 
contributing to intracellular aspects of infection. Furthermore, as 
suggest that the acquisition of ymt was an important step in the 
evolution of Y. pestis from Y. pseudotuberculosis to become a vector-
borne pathogen (Hinnebusch et al., 2002).
Using X. cheopis, researchers have also demonstrated that bio-
film production by Y. pestis is essential for proventriculus blockage 
and transmission (Hinnebusch et al., 1996; Jarrett et al., 2004a). 
Biofilm production has been attributed to a set of genes in the 
pigmentation (pgm) locus called the hemin storage (hms) locus. 
Hinnebusch and colleagues have demonstrated that unlike the ymt 
mutant, hms mutants are capable of prolonged colonization of the 
flea midgut. However, using microscopy, the researchers showed 
that hms mutants are defective in colonizing the proventriculus and 
forming aggregates. As proventriculus blockage is required for effi-
cient transmission, hms mutants are also defective in transmission 
from flea to mammal. Through use of the flea model, the researchers 
demonstrated that Y. pestis transmission can depend on factors that 
are not required for pathogenesis in the mammal.
While the flea is the natural insect vector for Y. pestis, the model 
poses some difficulties that may limit its widespread use in Y. pestis 
studies. These include a requirement for dedicated and specialized 
facilities to work with fleas, relatively slow growth of the insects, and 
a risk for Y. pestis transmission from flea to human. A second inver-
tebrate model that has recently emerged for studying Y. pestis-host 
interactions is the nematode Caenorhabditis elegans (Darby et al., 
2002, 2005; Joshua et al., 2003; Styer et al., 2005; Bartra et al., 2008). 
C. elegans is a simple, tractable model system that has been used to 
study pathogenesis of many microbes (see review by Darby, 2005). 
The nematode is easy to maintain and grows quickly. In addition, 
C. elegans grows at a similar temperature as X. cheopis (20–22°C). 
This means that many of the Y. pestis temperature regulated genes 
that are expressed during flea infection will likely also be expressed 
during C. elegans infection. Therefore, C. elegans may provide a 
simple system to screen for colonization and transmission factors 
of Y. pestis prior to further work with X. cheopis.
As seen in the flea, Y. pestis forms biofilms during C. elegans infec-
tion (Darby et al., 2002; Joshua et al., 2003). Biofilm formation inhibits 
the ability of C. elegans to feed and decreases survival of the worms. 
Mutational analysis confirmed that the hms genes were required for 
both biofilm formation and C. elegans death. Additional studies have 
demonstrated that C. elegans can be used to identify new potential 
transmission factors. Using a genetic screen, Darby et al. (2005) 
demonstrated that the gmhA gene of Y. pestis is involved in biofilm 
formation in C. elegans and is required for blockage of the flea prov-
entriculus. In addition, Styer et al. (2005) have demonstrated that Y. 
pestis can kill C. elegans through a biofilm-independent mechanism. 
The researchers showed that the Y. pestis KIM5 strain, which lacks the 
hms locus and the ability to make biofilms, colonizes the nematode 
intestinal tract and causes a lethal infection. They further demon-
strated that the pCD1 and pPCP1 plasmids were not required for 
death, indicating that the genes on these plasmids do not contribute 
to nematode colonization or death. Using a mutagenesis approach, the 
researchers also identified six novel Y. pestis factors that contributed to 
C. elegans death. They further demonstrated that two of these mutants 
were attenuated in the mouse model. These findings suggest that in 
addition to a model to identify Y. pestis factors important for the insect 
portion of the Y. pestis lifecycle, C. elegans may also be used to identify 
new pathogenesis factors involved in mammalian disease.Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 119  |  4
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vs. 2100 cfu, respectively), although only approximately 10% of 
the inoculum reaches the lungs via intranasal inoculation (Meyer, 
1950; Lathem et al., 2005). Bacterial numbers in the lungs steadily 
increase between 1 and 72 h post-infection regardless of inocula-
tion method. Lung pathology appears mild at 24 h but dramati-
cally worsens over the course of infection, resulting in large areas 
of consolidation and inflammation by 72 h. As seen in primary 
human pneumonic plague, bacteria disseminate from the lungs of 
infected mice to colonize the spleen by about 36 h post-infection. 
Interestingly, despite spleen colonization, Agar et al. did not detect 
bacteria in the blood until 72 h after aerosol inoculation (about 
24 h later than from intranasal infection (Sha et al., 2008)) when 
concentrations were greater than 104 cfu/ml (Agar et al., 2008). By 
both aerosol and intranasal infection, mice typically succumb to 
pneumonic disease 72–96 h after exposure (Lathem et al., 2005; 
Agar et al., 2008).
The  mouse  pneumonic  plague  model  demonstrated  that  a 
biphasic immune response occurs during plague infection (Lathem 
et al., 2005; Bubeck et al., 2007; Agar et al., 2008). During the first 
48 h of infection, Y. pestis steadily grows in the lungs of infected 
mice in the apparent absence of recognition by the host immune 
system. Concurrent with systemic spread of the infection, a sudden 
and strong inflammatory response is mounted by the host. This 
response includes induction of proinflammatory cytokines and 
chemokines and infiltration of PMNs into the lungs. Despite this 
massive response, Y. pestis appears to continue to grow unchecked. 
The combination of lung damage and an uncontrolled immune 
response results in death of the animals. This biphasic or delayed 
immune response differs from other Gram negative pneumonias. 
In the mouse model for Klebsiella pneumoniae, for example, mice 
mount a strong proinflammatory response within 24 h of intranasal 
infection, which includes induction of proinflammatory cytokines 
and chemokines and recruitment of PMNs into the lungs (Lawlor 
et al., 2006; Bubeck et al., 2007). These findings support the hypoth-
esis that Y. pestis actively modulates the immune response through 
effectors (Yops and LcrV) secreted by the type III secretion system 
encoded on the pCD1 virulence plasmid (see Cornelis and Wolf-
Watz, 1997; Viboud and Bliska, 2005 for reviews).
The mouse model has also been widely used to study interactions 
between Y. pestis and the mammalian immune system (for detailed 
reviews see Li and Yang, 2008; Smiley, 2008b). The availability of 
knockout and transgenic mice continues to make this an attractive 
model for immune system interaction studies. For example, from in 
vitro models and studies with enteric Yersinia, it has been hypoth-
esized that induction of IL-10 is important for Y. pestis to establish 
infection (Sing et al., 2002a,b). Despite this evidence, several studies 
of cytokine expression during plague infection have not been able 
to demonstrate a significant elevation in IL-10 levels in infected 
animals, suggesting that IL-10 does not play a role in plague infec-
tion (Lathem et al., 2005; Bubeck et al., 2007; Agar et al., 2008). 
Recently, DePaolo and colleagues used IL-10(−/−) knockout mice to 
test the hypothesis that IL-10 is involved in Y. pestis infection. The 
researchers demonstrated that IL-10(−/−) knockout mice displayed a 
significantly different immune response against Y. pestis CO92 and 
were protected from plague infection compared to wild type mice, 
supporting the hypothesis that Y. pestis induces IL-10 to establish 
infection (DePaolo et al., 2008).
we gain more understanding of the intracellular lifecycle of Y. pestis, 
the macrophage model will be important in developing therapeutic 
strategies targeted at intracellular Y. pestis.
mammalIan models to study Plague PatHogenesIs
Animal models ranging from rodents to NHPs have been used to 
study plague pathogenesis over the years. By far rodent models are 
the predominate choice of plague researchers. This choice is based 
on many factors, including cost, small size of the rodent models, 
and availability of facilities to perform containment work. However, 
vaccine and therapeutic studies require testing in NHPs prior to 
FDA approval. While all of the models discussed here are suscep-
tible to plague infection, each have caveats that could influence a 
researcher’s selection of a plague model.
the mouse model
The mouse is currently the most widely used animal model for 
plague research. The mouse is highly susceptible to plague infec-
tion and appears to be equally susceptible to different strains of Y. 
pestis (Butler, 1983; Adamovicz and Worsham, 2006). Furthermore, 
the mouse model is susceptible to pneumonic and intravenous 
infection (but not bubonic infection) by strains of Y. pestis lack-
ing the pgm locus (Burrows and Jackson, 1956; Une and Brubaker, 
1984). pgm(−) strains can be handled at BSL-2 and are exempt 
from Select Agent status (http://www.selectagents.gov/Exclusions.
html). Consequently, the mouse model can be used with pgm(−) 
strains by researchers who lack BSL-3 laboratories. However, while 
pgm(−) strains have been a useful tool to study plague, researchers 
need to take into consideration that pgm(−) strains are attenuated. 
Therefore, it is prudent that findings with pgm(−) strains, espe-
cially in the context of the host, be confirmed with fully virulent 
Y. pestis to ensure that the host does not react differently to the 
attenuated strain.
Recently, the kinetics of disease progression in the mouse model 
have been well characterized using the CO92 strain of Y. pestis 
(Lathem et al., 2005; Cathelyn et al., 2006; Agar et al., 2008). To 
model bubonic infection, mice can be infected via subcutaneous 
(s.c.) or intradermal injection. Disease progression via both routes 
is similar to transmission from infected fleas (Jarrett et al., 2004b). 
The LD50 during s.c. infection in this model is less than 10 colony 
forming units (cfu) (Cathelyn et al., 2006). After inoculation with 
∼102 cfu, Y. pestis can be detected in the draining lymph nodes as 
early as 24 h post-infection (M.B. Lawrenz and V.L. Miller, unpub-
lished data). The bacteria continue to replicate and reach high con-
centrations in these tissues, similar to human plague. However, 
lymphadenopathy may not be obvious until later stages of infection. 
Systemic infection begins 12–24 h after lymph node colonization 
and is evident by isolation of bacteria from the spleen at 48 h post-
infection. Lung colonization (secondary pneumonic plague) via 
systemic spread occurs after spleen colonization but is seen prior 
to the animals succumbing to infection. Death typically occurs 
between 3 and 5 days post-infection (Cathelyn et al., 2006).
Pneumonic infection of the mouse model can be achieved by 
intranasal or aerosol inoculation and results in an infection similar 
to human pneumonic plague (Lathem et al., 2005; Agar et al., 2008). 
The LD50 for intranasal infection with Y. pestis CO92 appears to be 
approximately 10-fold less than for aerosol inoculation (∼250 cfu www.frontiersin.org  November 2010  | Volume 1  | Article 119  |  5
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pneumonia resulting from dissemination through the blood stream 
(Strong and Teague, 1912a,b; Meyer, 1961). Evidence suggests that 
aerosol particle size determines whether primary pneumonia will 
develop. Compared to other models, it appears smaller particle sizes 
are required to deliver Y. pestis into the lungs of guinea pigs (Druett 
et al., 1956). Furthermore, intranasal inoculation does not appear 
as reliable in the guinea pig as reported for the mouse model and 
may not be a viable route for infection (Meyer, 1961).
The guinea pig can also show striking differences in susceptibility 
to different Y. pestis strains compared to other models. For example, 
the guinea pig model is highly resistant to auxotrophic strains that 
retain virulence in mice and NHPs (Burrows, 1960, 1963; Burrows 
and Gillett, 1971; Meyer et al., 1974b; Oyston et al., 1996). It has 
been suggested that physiological differences in free amino acids 
between species may be responsible for the differences seen in sus-
ceptibility. The guinea pig is also resistant to infection by Y. pestis 
strains lacking the F1 capsule that are virulent in the mouse model 
(Burrows and Bacon, 1958; Welkos et al., 1995). Therefore, it may 
be prudent to test any attenuated mutants or potential live vaccine 
candidates identified in the guinea pig model in other small animal 
models prior to progressing to primate studies.
the rat model
The rat has been intimately linked to the plague throughout history 
and is often associated with urban outbreaks of human plague. 
Like the mouse, the genetics and immunology of the rat have been 
well characterized, making it a useful tool for biomedical research. 
While susceptible to Y. pestis infection, until recently the rat has 
not been widely used in pathogenesis studies because of perceived 
variability  in  disease  progression  during  infection.  Chen  and 
Meyer (1974) reported that both laboratory and wild rats appear 
to have an increased resistance to plague infection compared to 
other rodent models. These studies indicated that the lethal dose 
could be as much as 1,000-fold higher for a subcutaneous infec-
tion compared to the mouse model. More recent work with the 
inbred Brown Norway strain of Rattus norvegicus suggests that the 
rat can be a reproducible model to study human plague. Disease 
manifestation in this rat strain closely recapitulates human infec-
tion and may be especially useful in studying interactions in the 
draining lymph nodes during bubonic infection. Sebbane et al. 
extensively characterized the Brown Norway model for bubonic 
plague infection. These studies demonstrated that Brown Norway 
rats are relatively susceptible to plague infection (∼250 bacteria 
needed to cause bubonic infection) (Sebbane et al., 2005). As seen 
in human bubonic plague, the proximal lymph nodes were the first 
tissues to be infected in the rat, followed later by the blood, spleen, 
and lastly, the distal lymph nodes. The draining lymph node was 
rapidly colonized by Y. pestis (as early as 6 h post-infection), and 
extracellular bacteria were visible by 24 h post-infection. As the 
infection progressed, bacterial numbers dramatically increased, and 
the researchers observed lymphadenopathy, hemorrhage, necrosis, 
and other pathologies characteristic of human buboes. Eventually, 
bacteria spread to the blood (bacteremia) and disseminated through 
the blood to the spleen (as seen in septicemic plague). The authors 
also reported an apparent delayed immune response in the lymph 
nodes, which was ineffective in controlling infection, similar to 
what has been seen in mice and NHPs.
The mouse model has also served as a tool to begin to under-
stand host determinants that may contribute to resistance to Y. 
pestis infection (Congleton et al., 2006; Turner et al., 2008, 2009; 
Blanchet et al., 2010). Recently, Blanchet et al. identified that the 
SEG mouse, an inbred Mus spretus line, is significantly more resist-
ant to infection by fully virulent Y. pestis compared to other more 
commonly used Mus musculus inbred lines such as C57BL/6. The 
subcutaneous LD50 in female SEG mice appears to be greater than 
107 bacteria compared to less than 10 for C57BL/6. The research-
ers identified three independent quantitative trait loci (QTL) that 
contribute to resistance to Y. pestis infection in an additive fashion 
(Blanchet et al., 2010). Although further analysis of these loci is 
needed to identify the genes responsible for increased resistance to 
plague infection, these studies may provide insight into possible 
differences in plague susceptibility in the human population.
The advantages of the mouse model to study pathogenesis also 
apply to its use in testing potential plague therapeutics. Numerous 
potential vaccines, including subunit, live-attenuated, killed, and 
DNA vaccine candidates, have been screened for efficacy in the 
mouse model (see Smiley, 2008a for review of vaccine candidates). 
In addition, novel therapeutics including monoclonal antibodies, 
new antimicrobial compounds, and new adjuvants to augment vac-
cine efficacy have also been studied in the mouse plague model 
(Uddowla et al., 2007; Amemiya et al., 2009; Eisele and Anderson, 
2009). However, it is important to consider that the differences 
between mouse and human anatomy and physiology may impact 
interpretations of therapeutic studies. For example, the respiratory 
tracts of mice and humans are dramatically different. Compared 
to humans, mice have increased surface area in their nasal pas-
sages, have only a single lobe in their left lung, lack bronchioles, are 
unable to cough in response to mechanical stimulation, and exhibit 
different immune potentials in the lungs (Irvin and Bates, 2003; 
Mizgerd and Skerrett, 2008). Furthermore, the immune system of 
mice is different than that of humans (Mestas and Hughes, 2004). 
Therefore, results from rodent models, especially in the case of 
therapeutic studies, need to be confirmed in models more closely 
related to humans, such as NHPs (see below), prior to being directly 
applied to human disease.
the guinea pig model
The guinea pig has been used as a plague model since the early 1900s 
and is still used in vaccine studies today (Jones et al., 2003; Qi et al., 
2010). Like the other small animal models, the guinea pig is highly 
susceptible to Y. pestis infection (subcutaneous LD50 < 10, aerosol 
LD50 ∼40,000) (Welkos et al., 1995; Titball and Williamson, 2001). 
Subcutaneous infection of the guinea pig results in the develop-
ment of papules at the infection site and lymphadenopathy in the 
draining lymph nodes. As in human plague, guinea pigs eventually 
develop septicemic infection and succumb to disease within 2 weeks 
(Pollitzer, 1954). It is important to note that the pneumonic guinea 
pig model can differ dramatically from the mouse and NHP mod-
els. Aerosol infections that initiate a primary pneumonia in mice 
or NHPs may not cause primary pneumonia in the guinea pig. Y. 
pestis introduced into guinea pigs by aerosol inoculation tends to 
initially colonize the cervical lymph nodes, indicating that infec-
tion originates from the upper respiratory tract. Infection of the 
lungs can occur, but it is delayed and appears to be a secondary Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 119  |  6
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important models to study plague and have provided useful insight 
into Y. pestis disease progression. Future studies with NHPs will be 
important in the successful development of plague vaccines and 
therapeutics. Three of the more widely used species to study plague 
are described here.
rhesus macaques
Progression of pneumonic plague in Rhesus macaques appears to 
be very similar to human infection (Speck and Wolochow, 1957; 
Finegold et al., 1968). As in humans, the disease has a short incu-
bation period and animals usually show the first sign of infection 
(fever) within 2 days after exposure. The mean day to death for 
infected Rhesus macaques is approximately 6 days, and animals 
developed all stages of pneumonia during the course of infection. 
Although disease progression appears similar to humans, Rhesus 
monkeys  are  significantly  more  resistant  to  plague  infection 
(Ehrenkranz and Meyer, 1955; Speck and Wolochow, 1957). The 
LD50 for Y. pestis in the Rhesus model can be as much as 10-fold 
higher for pneumonic infection and several thousand-fold higher 
for bubonic infection than other NHP models or the estimated 
infectious doses for humans. Furthermore, Rhesus macaques have 
demonstrated a tendency to develop a form of plague referred to 
as chronic pneumonic plague, which is very rarely seen in humans 
(Ransom and Krueger, 1954). These differences in the Rhesus model 
should be considered when using this model to evaluate pathogen-
esis of plague or new plague therapeutics.
african green monkeys
Unlike the Rhesus model, the African green monkey is highly 
susceptible to plague infection. The LD50 of Y. pestis appears to 
be slightly lower than the predicted doses for humans, with a 
LD50 ∼300 cfu by aerosol transmission and ∼5–50 cfu by intra-
dermal inoculation (Chen et al., 1977; Adamovicz and Worsham, 
2006). Despite this increased susceptibility, disease manifesta-
tions and pathology in aerosol infected African green monkeys 
are similar to human pneumonic plague patients (Layton et al., 
2010). Bacteria grow to high numbers in the lungs, resulting in 
severe pneumonia, and disseminate to the blood in as little as 
2 days post-infection. Monkeys develop fever at various time 
points post-infection, but in most cases fever was not observed 
until after bacteremia and approximately 24 h prior to succumb-
ing to infection. The mean time to death for aerosol infected 
African green monkeys is approximately 4 days post-exposure 
(Layton et al., 2010).
This model has shown some variability in susceptibility to the 
attenuated EV76 vaccine strain. This variability may be due to its 
increased susceptibility to Y. pestis as a species; however, some evi-
dence suggests that variability could be attributed to the origin 
of the subspecies used in the studies (Hallett et al., 1973). African 
green monkeys have also demonstrated a high degree of variabil-
ity in vaccine studies (Hallett et al., 1973; Chen et al., 1977; Pitt, 
2004). Both subunit and live vaccine candidates that have shown 
protection in other animal models show only partial protection in 
this model. It has been difficult to interpret this data, especially in 
the context of its implications for human response to vaccination, 
but the African green monkey may be a more stringent model than 
other NHPs for testing vaccine efficacy (Pitt, 2004). Additionally, 
More  recently,  researchers  have  further  characterized  the 
Brown Norway model during pneumonic infection (Agar et al., 
2009;  Anderson  et  al.,  2009).  Using  intranasal  inoculation, 
Anderson et al. (2009) demonstrated that the LD50 for Y. pestis 
CO92 in the rat was similar to that reported for mice (∼200 cfu). 
Independent experiments by Agar et al. (2009) confirmed this 
intranasal LD50 and further demonstrated that the LD50 for aero-
sol transmission was also similar to mice (∼1.6 × 103 cfu). During 
intranasal infection, rats appeared healthy until 36 h post-in-
fection, when they began to demonstrate a hunched posture. 
From this point the animal’s condition quickly worsened, with 
an approximate mean day to death between 3 and 4 days post-
infection. The authors reported that the animals did not appear 
to lose weight over the course of the infection (Anderson et al., 
2009). One striking difference in rats infected via aerosol was 
an apparent earlier development of lung inflammation. Acute 
inflammation was observed by 24 h in aerosol infected animals, 
compared to inflammation occurring after 36 h in the intranasal 
rat and pneumonic mouse models (Lathem et al., 2005; Bubeck 
et al., 2007; Agar et al., 2008). The rat pneumonic model also 
differed in the kinetics of bacterial growth in the lungs. Unlike the 
mouse model, which demonstrates a steady increase in bacterial 
numbers in the lungs from 12 to 72 h (Lathem et al., 2005), Y. 
pestis numbers did not appear to increase in the lungs of infected 
rats between 12 and 48 h, regardless of inoculation method (Agar 
et al., 2009; Anderson et al., 2009). During this time the bacteria 
disseminated into the blood and to other tissues. At 48 h, bacte-
rial numbers began to increase in the lungs. It is unclear whether 
this increase was due to outgrowth of Y. pestis in the lungs or 
arrival of systemic organisms to the lungs through recirculation. 
As observed in the mouse (Lathem et al., 2005; Bubeck et al., 
2007; Agar et al., 2008), the rat pneumonic model demonstrated 
that Y. pestis alters the immune response of its host to delay the 
expression of proinflammatory cytokines and chemokines (Agar 
et al., 2009). Furthermore, Agar et al. (2009) were also able to 
show rat to rat transmission (∼33% transmission rate), which 
has not been shown in mice. This finding suggests that the rat 
may be used to model person to person transmission of primary 
pneumonic plague.
The similarity in lymph node disease between humans and the 
rat suggests that the rat may be a particularly relevant model to 
examine pathogenesis in these tissues. Using the rat lymph node 
model, Sebbane et al. (2006) examined the Y. pestis gene expres-
sion profile in infected lymph nodes. This work demonstrated that 
in response to a strong host iNOS response in the lymph nodes, 
Y. pestis genes that protect the bacteria from reactive nitrogen 
species were upregulated. The work further demonstrated that 
inactivation of one of these upregulated genes, hmp, resulted in 
an increase in the LD50 of Y. pestis in the rat. Future studies to 
analyze host-Y. pestis interactions in the lymph node could benefit 
from the rat model.
non-Human PrImate models of Plague InfectIon
Non-human primates research is expensive and requires specialized 
expertise and facilities, which imposes limitations on its widespread 
use to study Y. pestis pathogenesis (Patterson and Carrion, 2005). 
Regardless, the close relationship of humans to NHPs make these www.frontiersin.org  November 2010  | Volume 1  | Article 119  |  7
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summary
While the models highlighted in this review may be used inter-
changeably, specific aspects of an individual model may provide 
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models. As new anti-plague prophylactic and therapeutic candi-
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esis and immune responses in these models will be important to 
understand correlates of protection that can be applied toward 
predicting success in humans.
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